Table. Characteristics of Study Participants by Self-reported Symptoms After SARS-CoV-2 Messenger RNA Vaccinationa.
| Characteristic | No symptoms (n = 373) | Local symptoms only (n = 109) | Systemic symptoms (n = 446) | P valueb |
|---|---|---|---|---|
| Age, mean (SD), y | 68 (12) | 69 (11) | 62 (12) | <.001 |
| Sex | ||||
| Male | 195 (52) | 38 (35) | 127 (28) | <.001 |
| Female | 178 (48) | 71 (65) | 319 (72) | |
| Race and ethnicity | ||||
| White | 362 (97) | 105 (96) | 426 (95) | .40 |
| Other racial or ethnic groupc | 10 (3) | 4 (4) | 20 (5) | |
| Missing | 1 (0) | 0 | 0 | |
| Vaccine | ||||
| BNT162b2 | 214 (57) | 41 (38) | 159 (36) | <.001 |
| mRNA-1273 | 159 (43) | 68 (62) | 287 (64) | |
| BMI, mean (SD) | 28 (5) | 28 (6) | 28 (6) | .87 |
| Smoking status | ||||
| Never | 191 (51) | 53 (49) | 242 (54) | .72 |
| Former | 146 (39) | 46 (42) | 170 (38) | |
| Current | 36 (10) | 10 (9) | 34 (8) | |
| Comorbidities | ||||
| Hypertension | 159 (43) | 45 (42) | 163 (37) | .21 |
| Diabetes | 39 (10) | 16 (15) | 47 (11) | .41 |
| Coronary heart disease | 32 (9) | 9 (8) | 31 (7) | .67 |
| Heart failure | 4 (1) | 3 (3) | 1 (0) | .03 |
| eGFR >60 mL/min/1.73 m2 | 344 (93) | 99 (93) | 425 (96) | .26 |
| Stroke or TIA | 12 (3) | 3 (3) | 8 (2) | .42 |
| Prior COVID-19 | 19 (5) | 6 (6) | 59 (13) | <.001 |
| MFI S-antibody reactive | 365 (98) | 108 (99) | 444 (99) | .08 |
| Log-antibody, mean (SD) | 8 (1) | 9 (1) | 9 (1) | <.001 |
| Time from vaccination, mean (SD), d | 118 (63) | 129 (67) | 122 (68) | .34 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); eGFR, estimated glomerular filtration rate; MFI, mean fluorescence intensity; TIA, transient ischemic attack.
a
Data are presented as number (percentage) of participants unless otherwise indicated. Participants were classified as having any systemic symptoms (fever, chills, muscle pain, nausea, vomiting, headache, and/or moderate to severe fatigue), local symptoms only (injection site pain and/or rash), or no symptoms after either messenger RNA vaccine dose.
b
P values are from the χ2 test or unpaired t test.
c
Other racial or ethnic group includes American Indian or Alaska Native, Asian, Black, and Hispanic or Latino.